Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review

Abstract

Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases.

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

“…reported a case series in patients with Familial Mediterranean Fever and SpA treated with the combination of anakinra or canakinumab with anti-TNF or anti-IL17 or tocilizumab. All patients achieved remission with some dual therapy combinations and no SAEs were revealed ( 53 ). Successful experiences with DTT in patients with PsA and severe atopic dermatitis with secukinumab and dupilumab was also reported, without significant AEs ( 54 ).…”